+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Postmenopausal Vaginal Atrophy Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768181
  • Report
  • 52 pages
  • VPA Research
UP TO OFF
until Sep 30th 2019
1 of 3

FEATURED COMPANIES

  • DKSH Holding Ltd
  • EndoCeutics Inc
  • Hormos Medical Oy
  • Italfarmaco Holding SpA
  • Novo A/S
  • PEPTONIC medical AB
  • MORE
The global clinical trial report- “2019 Postmenopausal Vaginal Atrophy Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Postmenopausal Vaginal Atrophy. It presents in-depth analysis of Postmenopausal Vaginal Atrophy clinical trials across markets and companies. The research work is for providing complete understanding into trends in Postmenopausal Vaginal Atrophy.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Postmenopausal Vaginal Atrophy clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Postmenopausal Vaginal Atrophy

The research work is prepared through extensive and continuous research on Postmenopausal Vaginal Atrophy trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Postmenopausal Vaginal Atrophy patients are identified
  • The report includes panorama of Postmenopausal Vaginal Atrophy clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Postmenopausal Vaginal Atrophy clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • DKSH Holding Ltd
  • EndoCeutics Inc
  • Hormos Medical Oy
  • Italfarmaco Holding SpA
  • Novo A/S
  • PEPTONIC medical AB
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Postmenopausal Vaginal Atrophy Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Postmenopausal Vaginal Atrophy Clinical Trials by Region
2.2.2 Average Enrollment of Postmenopausal Vaginal Atrophy Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Postmenopausal Vaginal Atrophy Treatment, 2019

3. Region wise Postmenopausal Vaginal Atrophy Clinical Trials
3.1 Asia Pacific Postmenopausal Vaginal Atrophy Clinical Trials by Country
3.2 Europe Postmenopausal Vaginal Atrophy Clinical Trials by Country
3.3 North America Postmenopausal Vaginal Atrophy Clinical Trials by Country
3.4 Middle East and Africa Postmenopausal Vaginal Atrophy Clinical Trials by Country
3.5 South and Central America Postmenopausal Vaginal Atrophy Clinical Trials by Country

4. Postmenopausal Vaginal Atrophy Clinical Trial Trends
4.1 Start Year wise Postmenopausal Vaginal Atrophy Clinical Trials
4.2 Phase wise Postmenopausal Vaginal Atrophy Clinical Trials
4.3 Trial Status wise Postmenopausal Vaginal Atrophy Clinical Trials
4.4 Trial Type wise Postmenopausal Vaginal Atrophy Clinical Trials

5. Postmenopausal Vaginal Atrophy Average Enrollment Trends
5.1 Average Enrollment in Postmenopausal Vaginal Atrophy Trials by Year
5.2 Average Enrollment in Postmenopausal Vaginal Atrophy Trials by Phase
5.3 Average Enrollment in Postmenopausal Vaginal Atrophy Trials by Status
5.4 Average Enrollment in Postmenopausal Vaginal Atrophy Trials by Type of Trial

6. Companies Participating in Postmenopausal Vaginal Atrophy Clinical Trials
6.1 Postmenopausal Vaginal Atrophy Trials by Sponsor Type
6.2 Postmenopausal Vaginal Atrophy Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Postmenopausal Vaginal Atrophy Trials- Phase 1
7.2 Postmenopausal Vaginal Atrophy Trials- Phase 2
7.3 Postmenopausal Vaginal Atrophy Trials- Phase 3
7.4 Postmenopausal Vaginal Atrophy Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Postmenopausal Vaginal Atrophy Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Figure 5: Europe - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Figure 7: North America - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Figure 9: Postmenopausal Vaginal Atrophy Clinical Trials by Phase
Figure 10: Postmenopausal Vaginal Atrophy Clinical Trials by Trial Status
Figure 11: Postmenopausal Vaginal Atrophy Clinical Trials by Type
Figure 12: Postmenopausal Vaginal Atrophy Clinical Trials by Sponsor Type
Figure 13: Postmenopausal Vaginal Atrophy Clinical Trials by Leading Sponsors
Figure 14: Postmenopausal Vaginal Atrophy Average Enrollment by Phase
Figure 15: Postmenopausal Vaginal Atrophy Average Enrollment by Trial Status
Figure 16: Postmenopausal Vaginal Atrophy Average Enrollment by Type
Figure 17: Postmenopausal Vaginal Atrophy- Average Enrolment by Type of Sponsors
Figure 18: Postmenopausal Vaginal Atrophy- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Postmenopausal Vaginal Atrophy Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Table 5: Europe - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Table 7: North America - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Postmenopausal Vaginal Atrophy Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Postmenopausal Vaginal Atrophy Average Enrollment by Phase
Table 15: Postmenopausal Vaginal Atrophy Average Enrollment by Trial Status
Table 16: Postmenopausal Vaginal Atrophy Average Enrollment by Type
Table 17: Postmenopausal Vaginal Atrophy- Average Enrolment by Type of Sponsors
Table 18: Postmenopausal Vaginal Atrophy- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • DKSH Holding Ltd
  • EndoCeutics Inc
  • Hormos Medical Oy
  • Italfarmaco Holding SpA
  • Novo A/S
  • PEPTONIC medical AB
  • Pfizer Inc
  • Quatrx Pharmaceutical Co
  • Shionogi & Co Ltd
  • TherapeuticsMD Inc
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4768181
Adroll
adroll